Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Homopolymers of amino acids (such as polylysine) can adopt α-helical structure at low temperature that is "melted out" at high temperatures. This helix–coil transition was once thought to be analogous to protein denaturation. The statistical mechanics of this transition can be modeled using an elegant transfer matrix method, characterized by two parameters: the propensity to initiate a helix and the propensity to extend a helix.
A self-described democratic socialist, Sanders is a progressive and left-wing populist who admires social democratic programs in Europe and supports workplace democracy via union democracy, worker cooperatives, and workers' management of public enterprises. He is a strong critic of contemporary neoliberal capitalism, which he calls "uber-capitalism", blaming it for such social ills as declining life expectancy and rising diseases of despair. He advocates universal, single-payer healthcare, paid parental leave, and tuition-free tertiary education. He supports lowering the cost of drugs by reforming patent laws to allow cheaper generic versions to be sold in the US. He supported the Affordable Care Act, though he said it did not go far enough. In November 2015, he gave a speech at Georgetown University about his view of democratic socialism, including its place in the policies of presidents Franklin D. Roosevelt and Lyndon B. Johnson. Defining what "democratic socialism" means to him, Sanders said: "I don't believe government should take over the grocery store down the street or own the means of production, but I do believe that the middle class and the working families who produce the wealth of America deserve a decent standard of living and that their incomes should go up, not down.
1. "Unichem, Optimus enter into strategic tie-up”. The Hindu Business Line.com. Published on 5 November 2018. 2. “Unichem to acquire 20% stake in Optimus group for Rs 120 cr”. Business-standard.com. Published on 5 November 2018. 3. “Unichem Labs gets USFDA nod for asthma drug”. Economictimes.com. Published on 4-July-2018. 4. “Unichem Labs' Ghaziabad unit gets EIR from USFDA” Thebusinessline.com. Published on 5 June 2018. 2018. 5. “Unichem Laboratories Gets ANDA Approval from U.S. FDA for Valsartan Tablets, USP.” Reuters.com. Published on 7 May 2018. 6. “How Torrent Pharma is integrating Unichem to boost its domestic business.” Business-standard.com. Published on 13 February 2018. 7. “Torrent Pharma completes acquisition of Unichem Laboratories Ltd.” Economictimes.com. Published on 14 December 2017. 8. “This conventional businessman is set for second innings”. Economictimes.indiatimes.com. Published on 4 November 2017. 9. “Unichem Labs gets EIR from USFDA for Goa facility” Economics times.com. Published on 30 June 2017. 10. "Unichem Lab appoints Mr. Bhagwat S. Dhingra as Chief Executive-Domestic Pharma". Moneycontrol.com. 13 August 2012. 11. "Contact Pharmaceutical Company India - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 12. "Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd". Indiainfoline.com. Retrieved 3 October 2010. 13. "BSE Plus". Bseindia.com. Retrieved 3 October 2010. 14. "Pharmaceutical Business, Pharma Business Development - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 15.
CH3OH + CO → HCO2CH3 In industry, this reaction is performed in the liquid phase at elevated pressure. Typical reaction conditions are 80 °C and 40 atm. The most widely used base is sodium methoxide. Hydrolysis of the methyl formate produces formic acid:
Sources: en.wikipedia.org
The visualization of single molecules, single cells, biological tissues, and nanomaterials is an important and attractive approach in analytical science. Also, hybridization with other traditional analytical tools is revolutionizing analytical science. Microscopy can be categorized into three different fields: optical microscopy, electron microscopy, and scanning probe microscopy. Recently, this field is rapidly progressing because of the rapid development of the computer and camera industries.
Pan frying (sauté) on stove top heat: 120 °C (248 °F) Deep frying: 160–180 °C (320–356 °F) Oven baking: Average of 180 °C (356 °F) Smoke point decreases at a different pace in different oils. Considerably above the temperature of the smoke point is the flash point, the point at which the vapours from the oil can ignite in air, given an ignition source. The following table presents smoke points of various fats and oils.
In several countries, the illegal drug trade is thought to be directly linked to violent crimes such as murder and gun violence. This is especially true in all developing countries, such as Honduras, but is also an issue for many developed countries worldwide. In the late 1990s in the United States, the Federal Bureau of Investigation estimated that 5% of murders were drug-related. In Colombia, drug violence can be caused by factors such as the economy, poor governments, and no authority within law enforcement. After a crackdown by US and Mexican authorities in the first decade of the 21st century as part of tightened border security in the wake of the September 11 attacks, border violence inside Mexico surged. The Mexican government estimated that 90% of the killings were drug-related. A report by the UK government's Drug Strategy Unit that was leaked to the press, stated that due to the expensive price of highly addictive drugs heroin and cocaine, drug use was responsible for the great majority of crime, including 85% of shoplifting, 70–80% of burglaries and 54% of robberies. It concluded "[t]he cost of crime committed to support illegal cocaine and heroin habits amounts to £16 billion a year in the UK"
Sources: en.wikipedia.org
Hydroxyzine's predominant mechanism of action is as a potent and selective histamine H1 receptor inverse agonist. This action is responsible for its antihistamine and sedative effects. Unlike many other first-generation antihistamines, hydroxyzine has a lower affinity for the muscarinic acetylcholine receptors, and in accordance, has a lower risk of anticholinergic side effects. In addition to its antihistamine activity, hydroxyzine has also been shown to act more weakly as an antagonist of the serotonin 5-HT2A receptor, the dopamine D2 receptor, and the α1-adrenergic receptor. Similarly to the atypical antipsychotics, the comparably weak antiserotonergic effects of hydroxyzine likely underlie its usefulness as an anxiolytic. Other antihistamines without such properties have not been found to be effective in the treatment of anxiety. Hydroxyzine crosses the blood–brain barrier easily and exerts effects in the central nervous system. A positron emission tomography (PET) study found that brain occupancy of the H1 receptor was 67.6% for a single 30 mg dose of hydroxyzine. In addition, subjective sleepiness correlated well with the brain H1 receptor occupancy. PET studies with antihistamines have found that brain H1 receptor occupancy of more than 50% is associated with a high prevalence of somnolence and cognitive decline, whereas brain H1 receptor occupancy of less than 20% is considered to be non-sedative. Hydroxyzine also acts as a functional inhibitor of acid sphingomyelinase.
=== Functional and bioactive components === Among the functional proteins detected in donkey milk, there are molecules active in antimicrobial protection such as lysozyme and lactoferrin. The lactoferrin content of donkey milk is intermediate between the lower values of cow milk and the higher values of human milk. Lactoferrin inhibits the growth of iron-dependent bacteria in the gastrointestinal tract. This inhibits certain organisms, such as coliforms and yeast, that require iron. Lysozyme in donkey milk is present in large amounts, and ranges from 1.0 mg/mL to 4 mg/mL, depending on the analytical method used (chemical or microbiological); This substance is present also in humans (0.12 mg/mL) but only in trace amounts in cow and goat milk. Lysozyme in donkey milk is highly thermo-stable and is very resistant to acid and protease and may play a significant role in the intestinal immune response. In donkey mammary secretion, defatted or not, growth factors and hormones have also been determined. Donkey mammary secretions contain human-like leptin at levels close to human milk (3.35 e 5.32 ng/mL milk). The bioactive peptides insulin-like growth factor 1, ghrelin, and triiodothyronine were also found in frozen donkey milk. These molecules and many others present in human milk, are increasingly receiving attention from a nutraceutical point of view because of their potential direct role in regulating food intake, metabolism, and infant body condition.
Before sequences can be analyzed, they are obtained from a data storage bank, such as GenBank. DNA sequencing is still a non-trivial problem as the raw data may be noisy or affected by weak signals. Algorithms have been developed for base calling for the various experimental approaches to DNA sequencing.
The southern districts of Le Havre are mainly used for industrial and port activities. There are buildings in brick from the 19th century, large developments (Chicago, Les Neiges), worker estates, SMEs, warehouses, dock and port facilities, and transport infrastructure. The southern districts have for some years experienced profound change due to European funding. It is revitalizing areas neglected by industrial and port activities by developing tertiary activities. Thus, the docks have been completely transformed into sports and entertainment complexes (Dock Océane), a mall (Docks Vauban), and an exhibition hall (Docks Café). Les Bains Des Docks was designed by the architect Jean Nouvel. At the end of 2012 students from Sciences Po's Europe-Asia undergraduate college campus and from INSA integrated new buildings next to the ISEL (Higher Institute of logistics studies) and the future ENSM (Ecole Nationale Supérieure Maritime). The new medical axis around the new Clinic des Ormeaux was built in the neighbourhoods where many homes are planned with the aim of promoting social mix. The City of the Sea and of Sustainable Development (Odyssey 21) will be organized around a metal tower one hundred metres high designed by Jean Nouvel: the project was suspended in 2007 but the work should finally begin in 2013. The municipality has to attract some 300,000 visitors per year.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.